# Zion Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zion-pharma

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.zionpharma.com
- Total disclosed funding: $73M
- Latest round: Series B (Jul 28, 2021)
- Investors on record: 6

## About

Based in Shanghai, China and established in 2018, Zion Pharma Limited is a bio-pharmaceutical company that focuses on the development of small molecule tumor drugs. Dr. Ziqiang Cheng, the company's co-founder and CEO, served as Director of Drug Metabolic Pharmacokinetics (DMPK) of AstraZeneca and GlaxoSmithKline

The company engages in the development of small molecule tumor drugs. Its main product is ZN-A-1041. ZN-A-1041 is a best-in-class small molecule tyrosine kinase receptor inhibitor targeting HER2. It is used in the treatment of HER2 and advanced breast cancer brain metastases. The company also created a new drug discovery platform.

## Funding rounds

- Series B, Jul 28, 2021, $40M — OrbiMed Advisors, Qiming Venture Partners, MED-FINE Capital, Sherpa Healthcare Partners, Ming Bioventures
- Series A, Jul 1, 2020, $20M — Qiming Venture Partners, MED-FINE Capital, Sherpa Healthcare Partners
- Series A, Jan 1, 2019, $10M — Qiming Venture Partners, MED-FINE Capital, TF Capital, Ming Bioventures
- Angel, May 1, 2018, $3M — MED-FINE Capital, TF Capital

## Investors

- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel, Series A, Series B
- TF Capital — Angel, Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B